Over the past five-and-a-half years, an average of more than 25 new molecule shortages have occurred annually, with 160 in total added through June of 2023 and only 51 resolved.
The ERISA Industry Committee has submitted a comment letter to the Ohio House of Representatives Insurance Committee urging the panel to amend House Bill 291 to include access to all biosimilar products.